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Introduction: The “International Nonproprietary Name (INN) pre-
scribing project” in Belgium aimed to operationalize electronic INN 
prescribing for outpatient care in daily medical practice and medical 
informatics.
Patients (or Materials) and Methods: The operationalization process 
consisted of 3 phases: (1) expert consultation; (2) review by regula-
tory authorities; and (3) test phase with stakeholders and end-users.
Results: The INN prescribing project resulted in: (1) operational 
rules for electronic INN prescribing; (2) the classification of the thera-
peutic arsenal, according to the operational rules; and (3) a refer-
ence database to be implemented in commercial medical software. 
The operational rules for electronic INN prescribing define valid 
INN groups as sets of equivalent medicinal products, described by 3 
elements: the therapeutic moiety (the active part of the therapeutic 
ingredient) or combination of therapeutic moieties, the strength (with 
standardized denominators), and the method of administration (with 
simplified but standardized options). The operational rules also define 
2 categories of exemptions for INN prescribing: INN groups where 
the first choice of treatment should be continued throughout the 
therapy period (NO SWITCH) and medicinal product groups not 
suitable for INN prescribing (NO INN).
Conclusion: Operationalizing INN prescribing for electronic pre-
scribing was a difficult yet feasible assignment. The INN prescribing 
project resulted into universally applicable operational rules and a 
corresponding classification of the therapeutic arsenal and reference 
database. These outcomes can be used by other countries planning 
to implement electronic INN prescribing.
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Introduction: Traditionally, the training in clinical pharmacology 
concentrated primarily on teaching of rational drug application for 
students and clinical therapists. Clinical medicines development is 
another important field of clinical pharmacology that requires a 
different training approach closely following the emergence of new 
scientific knowledge.
Results: A modern life-long learning concept for clinical pharma-
cologists must take into consideration the emerging new technologies 
of medicines development and application. The appearance of highly 
sensitive and noninvasive technologies to measure pharmacokinetic 
and pharmacodynamic parameters makes possible drug investigation 
in humans using extremely low doses without substantial danger for 
the volunteers at the very early stage of medicines development. These 
so-called Phase 0 trials permit to enrich the animal results with human 
pharmacologic data before initiating the classical human Phase I dose 
escalation study requiring more extensive animal toxicology. In early 
clinical development of new types of biological medicinal agents, 
drug-containing nanoparticles, medical device and drug combina-
tions, new pharmaceutical formulations routinely require a team of 
clinicians and natural scientists to perform jointly the complex tasks 
of the early learning phase of clinical medicines development. Beside 
profound knowledge in their primary clinical specialty, the new gen-
eration of clinical pharmacologists needs extensive additional train-
ing in the new methodologies of drug discovery, molecular biology, 
immunology, translational medicine, etc. for efficiently functioning 
in a multidisciplinary team.
Conclusion: At the Semmelweis University, the teaching of a reor-
ganized postgraduate training plan for clinical pharmacologists was 
initiated applying the principles outlined above. On the basis of our 
experience, an outline for a new national curriculum of clinical phar-
macology has been developed, which will be presented. The new 
plan takes over several topics and concepts worked out during the 
harmonization of pharmaceutical medicine education in Europe by 
PharmaTrain. A certain overlap in pharmaceutical medicinal and clini-
cal pharmacological curricula is desired, considering that the optimal 
clinical application of new types of medicines needs much more basic 
scientific knowledge than the use of traditional medicinal agents.
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Introduction: Drug manufacturers developed “evergreening strate-
gies” to compete with generic medication after patent termination. 
These include marketing of slightly modified follow-on drugs (slow-
release formulations, single isomer chiral molecules, active metabo-
lites, or structural analogues/combinations of original patented 
drugs) and offering high rebates to hospitals that use brand-name or 
evergreening drugs. The Geneva University Hospitals (HUG) and the 
Geneva community have different rules indeed. Drug prices are nego-
tiated and prescriptions restricted at HUG, while prices are fixed and 
prescriptions unrestricted in the community. We examine the impact 
of listing these drugs in the hospital-restrictive drug formulary (RDF) 
on the health care system as a whole (“spillover effect”).
Patients (or Materials) and Methods: We linked hospital and com-
munity pharmacy invoice office data in the Swiss canton of Geneva 
to calculate utilization of 8 follow-on drugs in defined daily doses 
between 2000 and 2008. This database includes > 73% of the total 
of insured patients. To examine the financial spillover effect, we cal-
culated a monthly follow-on drug market share in DDDs for medica-
tions prescribed by hospital physicians dispensed in the community 
(eg, at hospital discharge, in outpatient clinics) in comparison to 
drugs prescribed by physicians in the community. The spillover effect 
dynamic was analyzed under robust time series analysis using autore-
gressive integrated moving average (ARIMA) models.
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Results: The impact of strictly switching all proton pump inhibitors 
to esomeprazole at admission resulted in a spillover “extra-cost” of 
€ 330.3 (95% CI, 276.1 to 383.8) thousand, whereas strictly switch-
ing to generic cetirizine resulted in savings of € 7.7 (95% CI, –11.1; 
–4.1) thousand. Over the entire study period, we estimated that the 
RDF resulted in “extra-costs” of € 503.6 (95% CI, 444.5 to 563.1) 
thousand.
Conclusion: Hospitals may contribute to increased overall health 
care costs if follow-on drugs are listed in the RDF. Therefore, health 
care providers and policy makers should be aware of the impact of 
evergreening strategies.
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Introduction: There have been variable measures introduced in 
Scotland in recent years to take advantage of the availability of gener-
ics in high volume classes. Consequently, there is a need to assess their 
influence to provide guidance to authorities for the future.
Patients (or Materials) and Methods: A mixture of retrospective 
observational studies and interrupted time series analyses on subse-
quent drug utilization (DDDs [defined daily doses]) and expenditure 
of the various drugs in the different classes. Only administrative data-
bases used. Demand side measures recorded and categorized by 4Es 
(education, engineering, economics, and enforcement).
Results: (1) Multiple demand-side measures led to low-cost generic 
proton pump inhibitors (PPIs) driving the increase in utilization in 
recent years. PPI expenditure in 2010 was 56% below 2001 levels 
despite a 3-fold increase in utilization. The multiple measures saved 
the Scottish NHS GB£159 mn in 2010. Similarly for the statins, 
expenditure in 2010 was only 7% above 2001 levels despite a 6.2-
fold increase in utilization. Savings through the multiple measures 
were estimated at GB£290 mn in 2010. There was also increasing 
utilization of higher strength statins following quality targets and 
SIGN guidance. (2) Expenditure on renin-angiotensin inhibitor drugs 
in 2007 was similar to 2001 with multiple reforms to limit utilization 
of angiotensin receptor blockers (ARBs). (3) No specific measures 
to enhance the prescribing of losartan (first ARB to lose its patent) 
versus other ARBs. This resulted in no change in the utilization 
of losartan postgenerics. (4) pragmatic approach to generic clopi-
dogrel resulted in continuing high INN prescribing for clopidogrel 
and associated savings. (5) Measures to encourage the prescribing 
of generic SSRIs versus escitalopram reduced SSRI expenditure, fall-
ing by 59% between 2001 and 2007, despite increased utilization. 
SSRI expenditure increased in countries with limited demand-side 
measures. (6) No change in the utilization of risperidone postgenerics 
with no specific measures encouraging its use versus other atypical 
antipsychotics (AAPs).
Conclusion: Multiple demand-side measures appreciably enhanced 
prescribing efficiency in Scotland. This was helped by high INN pre-
scribing rates (98% to 99% in all classes studied) and low costs for 
generics. There was no spillover effect between classes, even if closely 
related, to enhance the prescribing of generics first line where no 
active reforms (eg, losartan or risperidone). However, the complex-
ity of treating schizophrenia and bipolar disorders may limit the 
potential to enhance the prescribing of generic AAPs first line where 
appropriate.
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Introduction: Generic losartan has been available across Europe, 
providing opportunities for authorities to save costs as all angioten-
sin receptor blockers (ARBs) are seen as similar in treating hyper-
tension and heart failure at appropriate doses. However, initiatives 
vary across Europe. Consequently, there is a need to assess changes 
in losartan utilization versus other ARBs alongside accompanying 
demand-side measures to provide future guidance.
Patients (or Materials) and Methods: Retrospective observational 
study using an interrupted time series design of patients dispensed 
at least 1 ARB in Austria, Belgium, Denmark, England (Bury PCT), 
Scotland, Spain (Catalonia), and Sweden up to 3 years before generic 
losartan was reimbursed and to up 3 years after. Defined daily doses 
and only administrative databases were used. Demand-side measures 
were recorded under the 4Es (education, engineering, economics, and 
enforcement). Prices for generic losartan were also recorded.
Results: There was appreciable variation in health authority activity. 
This ranged from delisting of all other ARBs from the reimbursement 
list in Denmark; easing of prescribing restrictions for losartan but not 
for other ARBs in Austria and Belgium; and formularies, incentive 
programs, and therapeutic switching in NHS Bury and Sweden, to 
no targeted activities in Spain or Scotland (due to other activities and 
other ARBs shortly losing their patents). Significant changes were 
seen in losartan utilization in Denmark (losartan 93% of total ARBs 
by study end), NHS Bury (losartan 65% of total ARBs by the end of 
the study). However, no change in losartan utilization postgenerics 
until active measures) and Sweden (losartan 40% of total ARBs). 
